Monday, May 3, 2021

DCAL | Stock Analysis and Price Outlook | Future Out performer

 

Dishman Carbogen Amcis Ltd.

Stock Price: 160


➽ Carbogen Amcis (India) Ltd provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.


Key  Summary


Promoters have decreased holdings from 61.93% to 59.32% in Mar 2021 qtr

Mutual Funds have decreased holdings from 10.25% to 8.81% in Mar 2021 qtr

Number of MF schemes remains unchanged at 6 in Mar 2021 qtr

FII/FPI have increased holdings from 5.22% to 6.38% in Mar 2021 qtr.

Number of FII/FPI investors decreased from 62 to 53 in Mar 2021 qtr

Institutional Investors have decreased holdings from 15.72% to 15.32% in Mar 2021 qtr


Financial Data Highlights

Market Cap2469.33
Book Value/ Share372.09
Enterprise Value477.32
Revenue TTM1894.57
Gross Profit TTM1519.38
Revenue /Share TTM120.32
Consensus Target398.14


ADVENZYMES | Stock Analysis And Price Outlook 


Financial Highlights DCAL

EOD Close157.65
Market Cap2469.33
EBITDA278.63
Book Value372.09
Profit margin0.0221
Qtr Revenue Growth YOY-0.136
Qtr Earning Growth YOY-0.816
Revenue TTM1894.57
Gross Profit TTM1519.38
Revenue Per Share TTM120.32
Face Value2.00
Enterprise Value477.32
Outstanding Shares15.68
Consensus Target398.14



Key Ratios of DCAL

Earning /Share2.66
Diluted EPS TTM2.66
PE Ratio59.27
Div / Share0.200
Div Yield %0.130
PEG Ratio0
Trailing PE59.27
Forward PE0
Price Sales TTM1.27
Price Book MRQ0.423
Enterprise Value / Revenue9.34
Enterprise Value / EBITDA1.71
Return on Asset TTM0.0148
Return on Equity TTM0.0160


GUJALKALI | Stock Analysis & Price Outlook   


Technical Chart & Price Outlook



Long position can be made for the potential upside level of 224 in  short to mid term and 374 in long term. 


HATSUN | Stock Analysis And Price Outlook 


Recent Valuation Summary


Rising Net Cash Flow and Cash from Operating activity

Company with Low Debt

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Book Value per share Improving for last 2 years

Company with Zero Promoter Pledge

FII / FPI or Institutions increasing their shareholding

Stock gained more than 20% in one month

Strong Momentum: Price above short, medium and long term moving averages


VIVIMEDLAB | Stock Analysis And Price Outlook 


Thanks for your Precious Time.


Finvest Online
Telegram  :  t.me/finvestonline






Disclaime
r- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader,user and company that are mention on this website.We are not SEBI registered financial advisor or analyst.


No comments:

Post a Comment